Swedish study questions safety of GE's Visipaque CT agent
This article was originally published in Clinica
Executive Summary
Contrary to previous findings, patients undergoing CT-guided percutaneous coronary interventions (PCI) using GE Healthcare's contrast agent Visipaque (iodixanol) are twice as likely to experience renal failure than those receiving alternative agents, Hexabrix (ioxaglate) or Omnipaque (iohexol). So say results of a study of over 50,000 patients presented at last month's annual meeting of the Radiological Society of North America (RSNA), in Chicago.